The core facts are settled: depression is real, common, disabling, and treatable, and both talking therapies and antidepressants outperform placebo on average. What remains genuinely unsettled is narrower: exactly how antidepressants work, how large the drug-placebo gap is, who responds to what, and whether depression is one condition or many. Keeping the settled and the unsettled apart is the whole point of reading the evidence well.
One distinction to hold onto
Most confusion about depression research comes from collapsing two separate questions. The first is why a treatment works, its mechanism. The second is whether it works, its effect in trials. These can have different answers. Aspirin relieved pain for decades before anyone understood how. In depression, the reverse worry applies to antidepressants: the popular serotonin explanation of how they work is not established, yet the trial evidence that they help many people on average is separate and reasonably robust. Throughout this page, keep those two threads distinct, because most of the heat in the public argument comes from tangling them.
This matters practically, not just philosophically. When the 2022 serotonin umbrella review was published, many headlines leapt to "antidepressants do not work," and some readers understandably stopped their medication. But that was not what the review found or claimed. It examined one hypothesis about the cause of depression and about how the drugs might act, and reported that the hypothesis lacked consistent support. Whether the drugs help is answered by a different body of research entirely: randomised trials comparing the drug with a placebo. Confusing the two led to real distress and, in some cases, abrupt withdrawal that can itself be harmful. Precision here is not pedantry; it changes what people do.
The evidence, sorted three ways
The panels below grade the main claims by how strong the evidence is. Green is settled, amber is mixed or evolving, red is genuinely contested. This is not a claim that contested questions are unanswerable, only that reasonable researchers still disagree.
Depression is real, common, and disabling. It affects hundreds of millions of people worldwide and is a leading cause of disability. It is not simply sadness or weakness; it has measurable effects on functioning, the body, and the risk of suicide.
Depression is treatable, and treatment beats no treatment. Talking therapies, especially cognitive behavioural therapy, outperform waiting-list and placebo conditions, and antidepressants outperform placebo on average across large trial datasets. Most people improve with appropriate treatment, though not everyone, and not always on the first attempt.
Depression is moderately heritable. Twin studies put heritability at roughly 35 to 40 percent. Genes matter, but there is no single depression gene, and the majority of risk comes from environment and life circumstances interacting with that inherited vulnerability.
How antidepressants work is not settled. The serotonin theory, that depression stems from a serotonin deficit the drugs correct, is not supported by consistent evidence, as the 2022 umbrella review concluded. Antidepressants clearly do something useful for many people, but the mechanism, whether through neuroplasticity, emotional processing, or effects we have not pinned down, remains an open scientific question. Unknown mechanism is not the same as no effect.
The size of the antidepressant advantage over placebo is debated. Meta-analyses agree the drugs beat placebo, but they disagree on how much, and averages hide wide variation. Some people benefit substantially, others little, and predicting in advance who will respond to which drug is still more art than science. Matching treatment to the individual remains an active research frontier.
Whether depression is over-diagnosed and over-medicated is genuinely disputed. Some researchers argue that normal responses to hard circumstances are increasingly labelled and medicated; others counter that under-treatment remains the bigger public-health problem. Both patterns can be true in different settings, and the debate is as much about health systems and thresholds as about the science.
How much to frame depression as biological versus social is unresolved. Emphasising biology can reduce blame but may also encourage a purely medical response; emphasising circumstance captures real causes but risks implying people should simply fix their lives. The evidence supports a combined biopsychosocial view, yet where to place the emphasis remains a values-laden argument.
Whether depression is one condition or many is an open question. The same diagnosis covers people with very different symptom profiles, triggers, and treatment responses. Many researchers suspect that what we call depression is really a cluster of related conditions, which would help explain why no single treatment works for everyone.
How depression is actually studied
Grading the evidence means knowing where it comes from. Different questions call for different methods, and each has characteristic strengths and blind spots. A twin study can estimate heritability but cannot tell you whether a pill works; a drug trial can measure an effect but not explain the biology behind it; a brain scan can show a difference but not prove it is a cause rather than a consequence. Reading depression research well means matching the claim to the method that can actually support it, and being wary when a strong claim rests on the wrong kind of study.
Twin and family studies
By comparing identical twins, who share all their genes, with fraternal twins, who share about half, researchers estimate how much of the variation in depression risk is inherited. This is how we arrive at the 35 to 40 percent heritability figure, and why we can say genes matter without claiming they determine the outcome.
Randomised controlled trials
To ask whether a treatment works, people are randomly assigned to the treatment or to a placebo or comparison, ideally without knowing which. Pooling many such trials in a meta-analysis, as Cipriani and colleagues did for 21 antidepressants, gives the most reliable read on average effects, though averages still hide individual variation.
Brain imaging and biology
Imaging and biochemical studies probe what is happening in the brain and body. They have found differences in stress-response and mood circuits, but no single reliable marker that defines depression, which is precisely why mechanistic claims, including the serotonin theory, have to be treated with caution.
The serotonin umbrella review
The 2022 review by Moncrieff and colleagues is itself a lesson in evidence: it did not run new experiments but pooled decades of existing studies to test one specific claim, that low serotonin causes depression, and found it unsupported. It is a model of separating a mechanism claim from questions about whether treatments help.
A few figures, in context
These come from large reviews and consensus sources. They are approximate and are meant to give a sense of scale, not false precision.
Reading the evidence honestly
The responsible summary is neither triumphant nor dismissive. Depression is real and treatable, and the treatments we have genuinely help many people. At the same time, the biology is less settled than confident slogans suggest, the average benefits are real but modest, and important questions about diagnosis, framing, and who benefits from what remain open. Holding both halves of that picture at once, that something can work even while we are still learning why, is the mark of engaging with the science as it actually stands.
It is also worth naming why the debate runs so hot. Depression sits at the meeting point of medicine, personal experience, and commerce, and each of those brings its own pressures. Drug companies have an interest in simple biological stories; some critics have an interest in the opposite; patients simply want to feel better and to know what is true. In that environment, headlines tend to flatten nuance into a slogan, either "proven brain disease" or "myth and marketing." Neither slogan survives contact with the actual literature. The evidence supports a more modest and more useful position: a real condition, shaped by biology and circumstance together, with treatments that help many though not all, and with plenty still left to learn. Distrust anyone who tells you it is simpler than that in either direction.
The bottom line: if you are considering treatment, the uncertainty about mechanism is not a reason to avoid help. The evidence that therapy and medication work for many people is separate from, and stronger than, any single theory about why. Decisions are best made with a clinician who can weigh the options for your situation.
Where to go next
For the everyday picture behind these findings, see the symptoms and causes. For how the settled evidence translates into practical help, read treatment.
Sources
- Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Molecular Psychiatry. 2023;28:3243-3256.
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391(10128):1357-1366.
- Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. American Journal of Psychiatry. 2000;157(10):1552-1562.
This page is educational and is not medical advice. It does not diagnose any condition or recommend any specific treatment, and nothing here should be read as a reason to start or stop medication on your own; decisions about treatment should be made with a qualified professional. If you are struggling, please speak with a doctor or mental health professional. If you are in crisis or thinking about harming yourself, contact your local emergency services or a crisis line now: in the UK and Ireland call Samaritans on 116 123, in the US call or text 988, or find your nearest helpline at findahelpline.com.